BioWorld

May 3, 2004

View Archived Issues

Sirna, Immune Response Pad Coffers With Private Placements

Read More

Genta, Allos Both Hurt By FDA Briefing Documents

Two firms scheduled to go before the Oncologic Drugs Advisory panel today took painful financial hits on Friday when FDA reviewers released unfavorable comments about their respective cancer treatments. (BioWorld Today) Read More

Biogen Idec Earnings Strong At Year's 'High-Water Mark'

Read More

Post-Meal Glucose Hangs Up Aradigm's Diabetes Treatment

Read More

Other News To Note

Read More

Appointments And Advancements

Read More